This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy
of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in
patients with stage IV non-squamous non-small cell lung cancer (NSCLC) without progressive
disease (PD), as confirmed on CT scans, after induction therapy with
carboplatin/pemetrexed/pembrolizumab (CPP) triplet therapy.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.